Context Therapeutics Inc is trading 5.4% higher at $1.46 in pre-market. This follows the announcement of positive interim Phase 1 clinical data for its CTIM-76 bispecific antibody in platinum-resistant ovarian cancer. Additionally, the company regained compliance with Nasdaq's minimum bid price rule. The move also aligns with a broader risk-on market tone, with major U.S. indices and futures trading notably higher on improved geopolitical sentiment.